Roche Holding AG’s product lineup is so strong that it can grow briskly even if it meets setbacks, the chief executive of the Swiss drugmaker told a newspaper.
“Roche could have six new active pharmaceutical ingredients approved within two years. We never had this before,” Severin Schwan told Finanz und Wirtschaft in an interview published on Friday.
{iframe}http://www.reuters.com/article/2015/09/25/roche-ceo-idUSL5N11V0Q920150925{/iframe}